Why Wave Life Sciences Stock Crushed it Again Today
Summarize this article with:
By Eric Volkman – Dec 9, 2025 at 7:19PMKey PointsIt wasn't hard to be optimistic about the biotech's future, given its excellent news from the lab on Monday.Prognosticators fell over themselves publishing bullish new takes on the company the following day.These 10 Stocks Could Mint the Next Wave of Millionaires ›NASDAQ: WVEWave Life SciencesMarket Cap$3.1BToday's Changeangle-down(15.07%) $2.79Current Price$21.31Price as of December 9, 2025 at 4:00 PM ETThere's nothing like a nearly 150% price gain to garner the attention of investors and analysts.The nearly 150% price pop Wave Life Sciences (WVE +15.07%) stock experienced on Monday was a hard act to follow. But the biotech's shares continued to be a hot item the following day, although that session's gain was "only" 15%. Investors continued to load up on the stock after an analyst's recommendation upgrade and several pundit price target raises. Here come the bulls Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 clinical study of WVE-007, its obesity drug candidate. Weight-loss drugs are all the rage these days in the U.S., which has many overweight people living within its borders. Image source: Getty Images. The medicine's solid performance inspired several analysts tracking it to publish bullish updates on its developer's stock. The most bullish of all was that recommendation upgrade, enacted by RBC Capital's Luca Issi. He now feels Wave stock rates an outperform (buy, in other words), one full notch up from his previous sector perform (hold). He also tripled his price target to $27 per share from $9. According to reports, Issi was impressed by WVE-007, which showed a quick effect on patients. The analyst also noted the weight loss it produced was comparable to that of Novo Nordisk's durably popular Wegovy, and it appears that Wave's drug is relatively easy on muscle mass. ExpandNASDAQ: WVEWave Life SciencesToday's Change(15.07%) $2.79Current Price$21.31Key Data PointsMarket Cap$3BDay's Range$17.90 - $21.7352wk Range$5.28 - $21.73Volume38MAvg Vol4.8MGross Margin91.99%Dividend YieldN/A Optimism incoming Several of Issi's peers were quick to bump their price targets higher, although he was the only one upgrading his Wave recommendation.Advertisement Among the raisers was Canaccord Genuity's Whitney Ijem, who more than doubled her fair value assessment to $40 per share from $19. Wells Fargo prognosticator Ben Burnett is also clearly impressed by the company, as he lifted his price target by $13 to $29 per share. I think this is only the start of an analyst bull stampede into Wave. WVE-007's results were compelling, and although it's still in its early stages of development, its promise already seems immense. This company is well worth watching.About the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanRead NextDec 8, 2025 •By Eric VolkmanWhy Wave Life Sciences Stock Vaulted 146% Higher on MondayOct 24, 2024 •By Alex Carchidi1 Brand-New Big Reason to Buy This Biotech Stock Right NowOct 3, 2024 •By Alex CarchidiBetter Biotech Stock: Wave Life Sciences vs. Sarepta TherapeuticsSep 19, 2023 •By Alex Carchidi2 Cutting-Edge Gene-Editing Stocks That You Don't Want to MissAug 11, 2022 •By Eric VolkmanWhy Wave Life Sciences Was Zooming Higher TodayMar 30, 2021 •By Brian Orelli, PhDHere's Why Wave Life Sciences Crashed Today